Case File
efta-efta00875577DOJ Data Set 9OtherFrom: Jeffrey Epstein <[email protected]>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00875577
Pages
4
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <[email protected]>
To: "McCaffrey, Carlyn"
Subject: Re:
Date: Sun, 10 Feb 2013 16:37:19 +0000
I. according to the strike, price, 2. the economic effect can be manged in the document. 3, security wise lock
up is only concern as long as it happens near the same time and is not deep in the money, 4, the price of the
option reflects the risk of that,
On Sun, Feb 10, 2013 at 12:27 PM, McCaffrey, Carlyn
> wrote:
What would the price of a 10 year option be?
Although he can buy the PS interest , the call will have to be on the stock itself.
Your structure bypasses 2703 because LB will never deliver the stock pursuant to the option. The economic
effect, however, is the same. That's why some think it doesn't work.
What are the securities law consequences of LB buying stock and the selling a call?
Does the purchaser of a publicly traded call risk the possibility that the stock value will not increase because
all the growth will be paid out in dividends?
On Feb 10, 2013, at 10:36 AM, "Jeffrey Epstein" <jeevacationg_igmail.com> wrote:
good first try, yes call options are publicly traded, we would do five to ten year terms„ he could purchase
the partner ship interest i guess, valuation the issue , he could decide on how much, we wouldn't need to
bypass 2703, the stock would be full value but there would be an liability against it , which could not be
ignored. he would not need much money to live as he would have the full dividends.
On Sun, Feb 10, 2013 at 11:16 AM, McCaffrey, Carlyn <
> wrote:
I agree (although at least one of my partners does not) that you can avoid the reach of section 2703 with a cash
settled option.
How would we price the option? Are call options on the stock publicly traded? How are dividends treated under
the normal stock option?
Here's how I understand your proposal.
Step 1- LB buys stock from Trust (T) for $1B. LB issues a $1B note to T bearing interest at X%. and secured by a lien
on his art. We need to discuss what X should be. We also need to think about the mechanics which are made a
little difficult by the fact that the stock is held in a partnership. We also need to think about the fact that much of
his art is already subject to a lien held by US Trust.
EFTA00875577
Step tt2 - LB sells a 2 year call to T. The price for the call is $.18 (obviously, a rough estimate); the strike price is the
current market price.
Step tt3 - During the 2 year period of the call, LB spends the $.1B on living expenses, taxes, art, etc.
Step tt4 -Alternative 1- the $1B worth of stock is now worth $1.2 B. LB owes T .2 Billion. He issues a note to settle
the option. No income tax consequences because of grantor trust rules. The trust is ahead but not as much as it
would have been if it hadn't entered into the transaction but LB's spending needs have been taken care of.
Step tt4 - Alternative 2 - the $18 worth of stock is still worth $16. LB owes T nothing. T has lost .1B, but LB's
spending needs have been taken care of.
Steptt5 - LB sells another 2 year call to T, etc.
There are no income tax consequences because of the grantor trust rules.
What are the securities law consequences? Are any of these transactions covered by Rule 16b? Do these
transactions have to be reported?
Is this what you had in mind?
Carlyn S. McCaffrey I Partner
•
LLP
From: Jeffrey Epstein [rnailto:jeeyacationOgrnail.corn]
Sent: Saturday, February 09, 2013 8:11 PM
To: McCaffrey, Carlyn
Subject:
EFTA00875578
i have reviewed the 2703 regs, i don't see the issue, if the trust buys an option, at market, today and the
stock goes up, the stock gets valued at the fair market , but the cash settled option comes due reducing the
value of the estate. , bringing the same net result. and even better if debra gets the stock with a step up,
what am i misssing?
■**********************************************************
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
IRS Circular 230 Disclosure: To comply with requirements imposed by the IRS, we inform you
that any U.S. federal tax advice contained herein (including any attachments), unless specifically
stated otherwise, is not intended or written to be used, and cannot be used, for the purposes of
(i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or
recommending to another party any transaction or matter herein.
This message is a PRIVILEGED AND CONFIDENTIAL communication. This message and all
attachments are a private communication sent by a law firm and may be confidential or protected
by privilege. If you are not the intended recipient, you are hereby notified that any disclosure,
copying, distribution or use of the information contained in or attached to this message is strictly
prohibited. Please notify the sender of the delivery error by replying to this message, and then
delete it from your system. Thank you.
Please visit http://www.mwe.com/ for more information about our Firm.
**********************************
*************************
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
EFTA00875579
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00875580
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]URL
http://www.mwe.comRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.